News

The $25 million upfront payment to Depomed under the agreement is due 60 days following completion of the Hart-Scott-Rodino Antitrust Improvements Act (HSR) review. Under the terms of

An additional approximately $267 million, or $3 per Indevus share, in cash will be payable in the future upon achievement of certain regulatory and sales milestones. The transaction

Cerepro was originally filed for marketing approval under exceptional circumstances in late 2005 and was reviewed by the European Medicines Regulatory Agency (EMEA) with reliance on Phase II

The collaboration which has been renewed several times and initiated in December 2002 focuses on the identification, development and commercialization of drugs for the treatment of neurodegenerative diseases,

An Independent Data Monitoring Committee (IDMC) has evaluated the interim results and concluded that the benefit-risk profile of zalutumumab is acceptable. The IDMC recommended that the trial should

The two Phase II, randomized, double-blind, placebo-controlled, dose-ranging studies enrolled a total of 157 patients and were conducted across 10 centers in the UK, Canada, and Australia. Multiple

The proposed indication in the marketing authorization application (MAA) is for the prevention of seasonal influenza. The MAA submission for live attenuated influenza vaccine (LAIV) is based on

Approved by the FDA under an investigational device exemption (IDE), the superficial femoral artery (SFA) study is a prospective, multicenter, single-arm trial planned to enroll 178 subjects at

The console powers Medtronic’s Midas Rex Legend EHS and Legend EHS Stylus drills, used primarily in spinal and cranial applications, and the Straightshot M4 Microdebrider, Visao, and Skeeter